Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15760643rdf:typepubmed:Citationlld:pubmed
pubmed-article:15760643lifeskim:mentionsumls-concept:C0033147lld:lifeskim
pubmed-article:15760643lifeskim:mentionsumls-concept:C0031268lld:lifeskim
pubmed-article:15760643lifeskim:mentionsumls-concept:C0032743lld:lifeskim
pubmed-article:15760643lifeskim:mentionsumls-concept:C0205100lld:lifeskim
pubmed-article:15760643lifeskim:mentionsumls-concept:C1751130lld:lifeskim
pubmed-article:15760643lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:15760643lifeskim:mentionsumls-concept:C0023981lld:lifeskim
pubmed-article:15760643lifeskim:mentionsumls-concept:C0059752lld:lifeskim
pubmed-article:15760643pubmed:dateCreated2005-3-11lld:pubmed
pubmed-article:15760643pubmed:abstractTextVinpocetine, a synthetic derivative of the Vinca minor alkaloid vincamine, is a widely used drug in neurological practice. We tested the hypothesis that vinpocetine binds to peripheral benzodiazepine binding sites (PBBS) and is therefore a potential ligand of PBBS. Positron emission tomography (PET) measurements in two cynomolgous monkeys showed that pretreatment with vinpocetine markedly reduced the brain uptake of [11C]PK11195, a known PBBS radioligand. On the other hand, whereas pretreatment with PK11195 increased the brain uptake of [11C]vinpocetine due to the blockade of PBBS in the periphery, it significantly reduced the binding potential (BP) values of [11C]vinpocetine in the whole brain and in individual brain structures to PK11195. These findings indicate that, whereas the two ligands have different affinities to PBBS, vinpocetine is a potent ligand of PBBS, which in turn suggests that the pharmacological activity of vinpocetine may involve the regulation of glial functions.lld:pubmed
pubmed-article:15760643pubmed:languageenglld:pubmed
pubmed-article:15760643pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15760643pubmed:citationSubsetIMlld:pubmed
pubmed-article:15760643pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15760643pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15760643pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15760643pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15760643pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15760643pubmed:statusMEDLINElld:pubmed
pubmed-article:15760643pubmed:monthMarlld:pubmed
pubmed-article:15760643pubmed:issn0022-510Xlld:pubmed
pubmed-article:15760643pubmed:authorpubmed-author:HalldinChrist...lld:pubmed
pubmed-article:15760643pubmed:authorpubmed-author:FardeLarsLlld:pubmed
pubmed-article:15760643pubmed:authorpubmed-author:GulyásBalázsBlld:pubmed
pubmed-article:15760643pubmed:authorpubmed-author:SzilágyiGézaGlld:pubmed
pubmed-article:15760643pubmed:authorpubmed-author:BURTJ HJHlld:pubmed
pubmed-article:15760643pubmed:authorpubmed-author:TihanyiKároly...lld:pubmed
pubmed-article:15760643pubmed:authorpubmed-author:BanatiRichard...lld:pubmed
pubmed-article:15760643pubmed:authorpubmed-author:ShchukinEvgen...lld:pubmed
pubmed-article:15760643pubmed:authorpubmed-author:FinnemaSjoerd...lld:pubmed
pubmed-article:15760643pubmed:authorpubmed-author:TarkainenJari...lld:pubmed
pubmed-article:15760643pubmed:issnTypePrintlld:pubmed
pubmed-article:15760643pubmed:day15lld:pubmed
pubmed-article:15760643pubmed:volume229-230lld:pubmed
pubmed-article:15760643pubmed:ownerNLMlld:pubmed
pubmed-article:15760643pubmed:authorsCompleteYlld:pubmed
pubmed-article:15760643pubmed:pagination219-23lld:pubmed
pubmed-article:15760643pubmed:meshHeadingpubmed-meshheading:15760643...lld:pubmed
pubmed-article:15760643pubmed:meshHeadingpubmed-meshheading:15760643...lld:pubmed
pubmed-article:15760643pubmed:meshHeadingpubmed-meshheading:15760643...lld:pubmed
pubmed-article:15760643pubmed:meshHeadingpubmed-meshheading:15760643...lld:pubmed
pubmed-article:15760643pubmed:meshHeadingpubmed-meshheading:15760643...lld:pubmed
pubmed-article:15760643pubmed:meshHeadingpubmed-meshheading:15760643...lld:pubmed
pubmed-article:15760643pubmed:meshHeadingpubmed-meshheading:15760643...lld:pubmed
pubmed-article:15760643pubmed:meshHeadingpubmed-meshheading:15760643...lld:pubmed
pubmed-article:15760643pubmed:meshHeadingpubmed-meshheading:15760643...lld:pubmed
pubmed-article:15760643pubmed:meshHeadingpubmed-meshheading:15760643...lld:pubmed
pubmed-article:15760643pubmed:meshHeadingpubmed-meshheading:15760643...lld:pubmed
pubmed-article:15760643pubmed:meshHeadingpubmed-meshheading:15760643...lld:pubmed
pubmed-article:15760643pubmed:meshHeadingpubmed-meshheading:15760643...lld:pubmed
pubmed-article:15760643pubmed:year2005lld:pubmed
pubmed-article:15760643pubmed:articleTitle[11C]vinpocetine: a prospective peripheral benzodiazepine receptor ligand for primate PET studies.lld:pubmed
pubmed-article:15760643pubmed:affiliationKarolinska Institute, Psychiatry Section, Department of Clinical Neuroscience, Karolinska Hospital, S-17176 Stockholm, Sweden. balazs.gulyas@neuro.ki.selld:pubmed
pubmed-article:15760643pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15760643lld:pubmed